The effect of Craviten, a new antiarrhythmic drug, its 2R, 2'R isomer, quinidine and procaine amide on human platelet aggregation.
Among the optical isomers of N, N'-dimethyl-N, N'-bis[1-(3', 4', 5-trimethoxybenzoyloxy)-butyl-2]-ethylenediamine dihydrochloride only the isomer with the (2S, 2'S) configuration (Craviten) in a concentration of 0.2 microgram/ml inhibits the ADP-induced aggregation of human platelets. The (2R, 2'R) isomer and quinidine exert a similar effect but only in a concentration ten times higher. Procaine amide (2 micrograms/ml) has an opposite effect, stimulating human platelet aggregation.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D005029:Ethylenediamines / Q000494:pharmacology*; D006801:Humans; D009564:Nitracrine / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011342:Procainamide / Q000494:pharmacology*; D011802:Quinidine / Q000494:pharmacology*; D013237:Stereoisomerism
D000889:Anti-Arrhythmia Agents; D005029:Ethylenediamines; C030706:butobendin; D000244:Adenosine Diphosphate; D009564:Nitracrine; D000255:Adenosine Triphosphate; D011802:Quinidine; D011342:Procainamide